Takeda, OTC Medicines Maker Unipharm Form Strategic Alliance
Takeda Pharmaceuticals has now signed a framework agreement with US-based specialist healthcare firm Unipharm. Under the deal, Takeda holds an option to purchase various over-the-counter (OTC) medicines and food supplements such as Vitrum, Artra, and Melaxen from Unipharm.
These products are for promotion and sale primarily in Russia, where Takeda has a strong presence providing innovative medicines, primary care medicines and OTC products to its people and patients. The portfolio is a strong strategic fit with Takeda’s Russian OTC business.
Under the framework agreement, Takeda has already acquired certain brands within the Vitrum range of multivitamin products and expects to complete the remaining conditions of the deal during this year.
Takeda Emerging Markets business unit president Ricardo Marek said: “This agreement demonstrates Takeda’s commitment to better health for patients across emerging markets with a range of trusted and proven products.”
